首页> European urology> Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.

Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Johann S,de Bono

第一单位： Institute of Cancer Research and Royal Marsden Hospital London UK.

作者： Johann S,de Bono ^[1] ; Meng,He ^[2] ; Zhen,Shi ^[2] ; Malgorzata,Nowicka ^[3] ; Sergio,Bracarda ^[4] ; Cora N,Sternberg ^[5] ; Kim N,Chi ^[6] ; David,Olmos ^[7] ; Shahneen,Sandhu ^[8] ; Christophe,Massard ^[9] ; Nobuaki,Matsubara ^[10] ; Geng,Chen ^[2] ; Nives Selak,Bienz ^[3] ; Daniel,Canter ^[2] ; Matthew,Wongchenko ^[2] ; Christopher,Sweeney ^[11]

作者单位： Institute of Cancer Research and Royal Marsden Hospital London UK. ^[1] Genentech South San Francisco CA USA. ^[2] F. Hoffmann-La Roche Basel Switzerland. ^[3] Azienda Ospedaliera Santa Maria Terni Italy. ^[4] Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, NewYork-Presbyterian New York NY USA. ^[5] BC Cancer Vancouver Canada. ^[6] Instituto de Investigación Sanitaria, Hospital Universitario 12 de Octubre Madrid Spain. ^[7] Peter MacCallum Cancer Centre and University of Melbourne Melbourne Australia. ^[8] Institut Gustave Roussy Villejuif France. ^[9] National Cancer Center Hospital East Chiba Japan. ^[10] South Australian Immunogenomics Cancer Institute, University of Adelaide Adelaide Australia. Electronic address: christopher.sweeney@adelaide.edu.au. ^[11]

关键词 Ipatasertib PTEN Prostate cancer